Key Highlights

  • Shares trading down 0.66% to $17.38 in today's session.
  • Trading Volume reached 9.02 million shares.
  • The company reported a trailing P/E ratio of 6.63 and an EPS of $2.52.
  • The deal is expected to be immediately accretive to the company's financial guidance.

Viatris to Acquire Pacira for $1.65 Billion in Cash

Viatris Inc. (NASDAQ:VTRS), a global healthcare company formed in 2020 through the Merger of Mylan and Pfizer's Upjohn division, agreed to acquire Pacira BioSciences for $36.50 per share in cash, valuing the deal at approximately $1.65 billion. The Acquisition will be carried out through a tender offer followed by a merger, with closing expected by the end of 2026.

Deal Adds Established Non-Opioid Pain Products

The acquisition brings two established, patent-protected products into the company's portfolio, EXPAREL for postsurgical pain and ZILRETTA for knee osteoarthritis pain, which together generated roughly $746 million in Revenue and $177 million in adjusted EBITDA over the past year. Management said the products are synergistic with its existing fast-acting meloxicam opportunity in non-opioid pain management.

Shares Dip Slightly in a Typical Acquirer Reaction

Shares slipped modestly today, with a trailing P/E ratio of 6.63 and an EPS of $2.52 reflecting the company's established, profitable base business. The company said it expects to fund the transaction primarily from excess cash, with minimal impact on its gross leverage ratio, and that the deal should be immediately accretive to its financial guidance metrics.

Outlook: Deal Expected to Close by Year-End

The transaction remains subject to a majority tender of Pacira shares and regulatory clearance, with closing expected by the end of 2026. The company's third-quarter results, scheduled for early November, may provide further detail on how the deal fits into its broader Long-term Growth targets.